SWOG S0722: Phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM)

INTRODUCTION: The PI3K/Akt/mTOR pathway is activated in a majority of malignant pleural mesotheliomas (MPM). We evaluated the activity of everolimus, an oral mTOR inhibitor, in patients with unresectable MPM. METHODS: MPM patients who had received at least one but no more than two prior chemotherapy...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:J Thorac Oncol
Main Authors: Ignatius Ou, Sai-Hong, Moon, James, Garland, Linda L., Mack, Philip C., Testa, Joseph R., Tsao, Anne S., Wozniak, Antoniette J., Gandara, David R.
Format: Artigo
Sprog:Inglês
Udgivet: 2015
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4304604/
https://ncbi.nlm.nih.gov/pubmed/25611229
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JTO.0000000000000360
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker